History

Turinabol was developed by Jenapharm in East Germany (GDR), patented in 1961 and introduced for clinical use in 1965 — the company's first original product. It is the 4-chloro derivative of metandienone (Dianabol), conceptually combining structural features of clostebol and metandienone, an idea attributed to Jenapharm chemist Albert Stachowiak. Production was discontinued in 1994. It became the signature drug of the GDR's state doping program ("State Plan Topic 14.25"), documented in detail by Franke and Berendonk (Clinical Chemistry, 1997).

Turinabol — chlorodehydromethyltestosterone (CDMT/DHCMT) — is an orally active 17α-alkylated anabolic-androgenic steroid (AAS), structurally the 4-chloro derivative of metandienone (“Dianabol”). It is best known historically as the signature drug of East Germany’s state doping program, where it was administered to thousands of athletes, including minors and adolescent girls, often without informed consent. It is an anabolic steroid, not a peptide.

What it is

Turinabol’s chemical identity is 4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-one (formula C₂₀H₂₇ClO₂; molar mass ~334.9 g/mol; CAS 2446-23-3). Structurally it carries 17α-methylation (a 17-alpha-alkyl group) and a 4-chloro substituent on the 1,4-diene-3-one A-ring. The 17α-alkyl group slows first-pass hepatic metabolism, which gives the drug oral bioavailability — but that same modification is what makes 17α-alkylated orals hepatotoxic (see Safety). Unlike testosterone enanthate/cypionate or nandrolone decanoate, Turinabol is not administered as an injectable ester, so there is no “ester timing” associated with it.

Mechanistically, like other AAS it binds and activates the intracellular androgen receptor (AR), driving anabolic effects (skeletal-muscle protein synthesis, nitrogen retention) alongside androgenic effects. Its 4-chloro/1,2-double-bond structure means it does not aromatize to estrogen, so estrogen-driven water retention and gynecomastia from the drug itself are minimal — historically the basis for marketing it as giving “dry,” lean-tissue gains. Reported pharmacokinetics (high oral bioavailability, hepatic metabolism, terminal half-life ~16 h, renal excretion) trace to encyclopedic/reference sources rather than a primary pharmacokinetic trial, so the exact half-life should be treated as approximate.

The claims

Turinabol is claimed to produce “lean” or “dry” muscle and strength gains with a favorable dissociation of anabolic from androgenic activity (“relatively mild androgenicity”). Those ratio claims derive from older animal assays (rat levator-ani/ventral-prostate), not clean human data, and should be treated cautiously. As an East German prescription product, it was used in the general AAS therapeutic space of its era — for example, promoting anabolism and recovery in debilitating or wasting conditions — though precise approved-indication wording is not well documented in reliable English-language sources.

What the evidence actually shows

There are no modern, controlled, randomized clinical trials of Turinabol specifically measuring lean mass or strength in athletes. Efficacy claims rest on (a) the GDR program’s internal records and performance outcomes — which are not controlled trials — and (b) extrapolation from the general androgen-dose-response literature.

The general androgen evidence (not Turinabol-specific) is real: supraphysiologic androgen exposure reliably increases fat-free mass and muscle strength in men, established for testosterone in controlled trials. This class effect is the basis for assuming Turinabol increases lean mass and strength, but the magnitude for Turinabol itself is not quantified by rigorous human trials. The bulk of credible recent scientific literature on Turinabol concerns anti-doping metabolite detection — including the controlled-administration pharmacology study of DHCMT (Loke et al., 2021) — not therapeutic efficacy.

Its relevance in modern sport is as a doping agent with a notable detection history: novel long-term metabolites proposed around 2011–2012 enabled adverse retests of stored 2008 and 2012 Olympic samples, and Turinabol accounts for a large share of the IOC’s retrospective anti-doping rule violations from that retesting program.

Bottom line for an evidence-first reader: claims of large “lean/dry” gains are historically and anecdotally reported but not supported by controlled human efficacy trials of this specific compound. The only directly applicable trial-grade data are animal ratio assays and human anti-doping pharmacology, not efficacy.

Legal and regulatory status

Turinabol was never FDA-approved in the United States; it was an East German (Jenapharm) product and was not marketed as an approved drug in the US. This contrasts with several other AAS — oxandrolone, oxymetholone, nandrolone, methyltestosterone, fluoxymesterone — which did or do have FDA approval for specific indications.

In the US, anabolic-androgenic steroids are Schedule III controlled substances under the Controlled Substances Act, via the Anabolic Steroids Control Act of 1990 (a provision within Pub. L. 101–647, effective Feb 1991) and the Anabolic Steroid Control Act of 2004 (Pub. L. 108–358, effective Jan 2005, which expanded the statutory list and removed the requirement to prove that a substance promotes muscle growth). Turinabol/CDMT falls within the statutory definition of an anabolic steroid and is therefore a Schedule III controlled substance (21 CFR 1308.13(f)); non-prescription possession or distribution is illegal.

In sport, Turinabol is a prohibited anabolic agent under WADA Class S1 (Anabolic Agents), subsection S1.1 (exogenous anabolic-androgenic steroids). S1 substances are prohibited at all times, both in- and out-of-competition.

Safety

Turinabol is the signature drug of the GDR state doping program (“State Plan Topic 14.25”). Per the landmark documentation by Franke and Berendonk (1997), from the mid-1960s the GDR systematically administered androgens to several thousand athletes per year — including minors and, with deliberate emphasis, women and adolescent girls (because androgenization produced the largest relative performance gains in females) — often without informed consent and frequently disguised as “vitamins.” Damaging side effects, some requiring medical or surgical intervention, were recorded in the regime’s own files. Specific human safety data for Turinabol alone is limited; the following reflects the well-documented risks of 17α-alkylated oral AAS as a class, which apply to Turinabol.

Hepatotoxicity (specific to 17α-alkylated orals): Per NIH LiverTox (“Androgenic Steroids”), 17α-alkylated androgens cause transient, usually asymptomatic aminotransferase elevations; acute cholestatic “bland” jaundice (typically within 1–4 months); peliosis hepatis (blood-filled hepatic sinusoids that can rupture and hemorrhage); and hepatic tumors — benign adenomas and, rarely, hepatocellular carcinoma — generally after years of use. Non-17α-alkylated (esterified/injectable) testosterones are only rarely implicated, underscoring that the 17α-alkyl group drives the liver risk.
Cardiovascular / lipid: AAS strongly suppress HDL (“good”) cholesterol and raise LDL, an atherogenic profile. The controlled study by Baggish et al. (Circulation 2017) found long-term AAS users had reduced LV systolic function (mean LVEF 52±11% vs 63±8% in non-users; lower still, ~49%, in current users) and impaired diastolic function, plus greater coronary atherosclerotic plaque volume correlating with lifetime AAS exposure. Reported AAS cardiovascular harms include hypertension, cardiomyopathy/LV dysfunction, accelerated atherosclerosis, and arrhythmia/sudden-death risk.
HPTA suppression and fertility: Exogenous androgens suppress the hypothalamic-pituitary-gonadal axis, lowering LH/FSH and endogenous testosterone, causing testicular atrophy, impaired spermatogenesis, and infertility, which can persist after discontinuation.
Gynecomastia: Although Turinabol does not itself aromatize, AAS-induced endocrine disruption can still contribute to gynecomastia risk in the broader context of androgen use.
Virilization (women): Irreversible or partly irreversible androgenic effects — deepened voice, hirsutism, clitoromegaly, menstrual disruption. The GDR program produced well-documented virilization in female athletes (Franke and Berendonk 1997).
Other: Possible erythrocytosis/raised hematocrit (thrombotic risk), acne, androgenic alopecia, mood/aggression and dependence syndromes, and — in adolescents — premature epiphyseal closure. The Endocrine Society scientific statement (Pope et al. 2014) provides the broad adverse-effect synthesis for the AAS class.

Bottom line

Turinabol is an orally active 17α-alkylated anabolic-androgenic steroid, not a peptide. Despite its historical reputation for “dry, lean” gains, there are no modern controlled human efficacy trials of the compound itself — its claimed effects rest on older animal ratio assays and class-wide androgen extrapolation, while the credible modern literature on it is dominated by anti-doping detection. It was never FDA-approved, is a Schedule III controlled substance in the US, and is banned at all times in sport (WADA S1.1). It carries the full hepatic, cardiovascular, endocrine, and (in women) virilizing risk profile of oral AAS, and its history is inseparable from the coercive, non-consensual East German state doping program.

Evidence grade: Animal only.

Turinabol (Oral Turinabol)